BSE Pharma Sector Regulatory Filings — June 04, 2026

Q4 FY26 consolidated revenue grew 8% YoY to ₹9,646 crore, driven by domestic formulation (+12% YoY to ₹853 crore) and export formulation (+9% YoY to ₹2,083 crore), outperforming the sector's average growth

Stand-alone EBITDA margin improved 252 bps YoY to 25.18% from 22.66%, indicating strong operational efficiency and cost control at the parent level

Management guided for 12-13% consolidated revenue growth in FY27, accelerating from the 8% YoY achieved in Q4 FY26, signaling confidence in demand recovery

Consolidated EBITDA margin guidance of ~22-22.3% for FY27 implies a potential 100-130 bps improvement from Q4 FY26's 21% (estimated), suggesting margin recovery expectations

Institutional business declined 24% YoY to ₹270 crore from ₹355 crore, a significant drag on overall performance that warrants monitoring

Unichem's EBITDA margin fell 400 bps YoY to 8% from 12%, indicating integration challenges or operational issues at the subsidiary level

No insider activity, capital allocation changes, or financial metrics reported; the filing is purely administrative with no investment signal

Input material costs surged 10-12% overall, with solvents up 40-50% and packaging materials (aluminum, PVC/PVDC) rising significantly, threatening future margin expansion

Revenue from institutional business dropped 24% YoY (₹270 crore vs ₹355 crore), a sharp contraction that could signal loss of contracts or pricing pressure in that segment

Unichem's EBITDA margin collapsed 400 bps YoY to 8%, dragging consolidated margins and suggesting potential structural issues or higher costs at the subsidiary

Management flagged a 10-12% increase in input material costs, with solvents up 40-50% and packaging materials rising significantly, which could compress margins if not passed through

FY27 EBITDA margin guidance of ~22-22.3% is below the Q4 FY26 stand-alone margin of 25.18%, implying that consolidated margins will remain under pressure from Unichem and cost inflation

While stand-alone margins improved, consolidated margins likely lagged due to Unichem's weakness; investors need to monitor the pace of subsidiary turnaround

Unclaimed dividends for FY ended March 31, 2019, will result in share transfer to IEPF after August 31, 2026; shareholders who miss the deadline lose direct ownership, though this is a low-probability event for most

Domestic formulation grew 12% YoY to ₹853 crore, outpacing the overall revenue growth; this segment's momentum could be a key driver for FY27 guidance achievement

Export formulation rose 9% YoY to ₹2,083 crore, indicating healthy demand in regulated markets; continued outperformance could support revenue acceleration

With FY27 EBITDA margin guidance of ~22-22.3% versus Q4 FY26 estimated consolidated margin of ~21%, there is potential for 100-130 bps expansion; if cost inflation eases, upside to guidance is possible

Management's 12-13% revenue growth guidance for FY27 implies acceleration from 8% YoY in Q4 FY26; successful execution could lead to earnings upgrades

Unichem's margin decline to 8% may be cyclical or integration-related; a recovery to historical levels (12%+) could add 100-150 bps to consolidated margins, offering significant upside

Shareholders with unclaimed dividends from FY 2019 have until August 31, 2026, to claim; proactive investors can acquire shares from unaware holders at a discount before the deadline, though this is a niche strategy

IPCA's domestic formulation grew 12% YoY, outpacing overall revenue growth of 8%, suggesting that the Indian pharma market remains robust and may be a key growth driver for sector players [IMPLICATION: Focus on companies with strong domestic franchises]

IPCA reported a 10-12% increase in input costs, with solvents up 40-50% and packaging materials rising significantly; this is likely a sector-wide issue that could pressure margins across BSE PHARMA in FY27 [IMPLICATION: Monitor cost pass-through ability and hedge strategies]

Unichem's 400 bps margin decline at IPCA highlights the challenges of integrating acquisitions; investors should scrutinize subsidiary performance in other pharma conglomerates for similar drags [IMPLICATION: Prefer companies with clean, focused operations]

While IPCA's export formulation grew 9% YoY, its institutional business declined 24% YoY, reflecting divergent demand in different export channels; sector-wide, institutional segments may face headwinds from pricing or tender delays [IMPLICATION: Favor companies with diversified export portfolios]

IPCA's FY27 revenue guidance of 12-13% growth is optimistic given current cost inflation and subsidiary issues; sector-wide guidance will be a key test of management credibility in upcoming earnings calls [IMPLICATION: Track guidance vs actuals closely for early warning signals]

Due by mid-August 2026; watch for revenue trajectory vs 12-13% guidance and margin trends amid input cost inflation

Monitor subsidiary margin improvement in coming quarters; a sustained 8% margin could lead to impairment or restructuring

Track solvent and packaging material prices; any further escalation could force guidance downgrades

Watch for commentary on institutional contract wins or losses in Q1 FY27; continued decline would be a red flag

August 31, 2026, is the last date for claiming unclaimed dividends from FY 2019; any surge in share transfers could create temporary price dislocations

Peer companies' earnings calls in coming weeks will reveal if cost inflation is sector-wide; IPCA's 10-12% increase may be a bellwether

With stand-alone margins at 25.18% but consolidated guidance at ~22%, the gap indicates subsidiary drag; narrowing this gap would be a positive catalyst